Werewolf Therapeutics (NASDAQ:HOWL) Upgraded at Zacks Research

Zacks Research upgraded shares of Werewolf Therapeutics (NASDAQ:HOWL) from a hold rating to a strong-buy rating in a research note released on Monday,Zacks reports.

Several other equities research analysts have also recently issued reports on the stock. Weiss Ratings raised shares of Werewolf Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, September 10th. Wall Street Zen raised Werewolf Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 22nd. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $4.00.

Werewolf Therapeutics Stock Performance

Shares of Werewolf Therapeutics stock opened at $0.92 on Monday. The business has a 50-day simple moving average of $0.77 and a 200-day simple moving average of $0.64. Werewolf Therapeutics has a one year low of $0.27 and a one year high of $2.13. The company has a market cap of $44.72 million, a PE ratio of -1.21 and a beta of 0.51.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its earnings results on Friday, July 31st. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.36. The firm had revenue of $21.00 million during the quarter, compared to analyst estimates of $21.00 million. On average, sell-side analysts predict that Werewolf Therapeutics will post -0.89 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Werewolf Therapeutics

Several large investors have recently modified their holdings of HOWL. Bank of America Corp DE acquired a new position in shares of Werewolf Therapeutics in the 2nd quarter valued at $112,000. Squarepoint Ops LLC acquired a new stake in Werewolf Therapeutics during the 2nd quarter worth $37,000. Finally, BlackRock Inc. acquired a new stake in Werewolf Therapeutics during the 2nd quarter worth $37,000. 64.84% of the stock is owned by institutional investors and hedge funds.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing investigational cancer immunotherapies. The company’s programs are designed to stimulate the immune system within the tumor microenvironment while limiting activity in healthy tissues, with the goal of improving the effectiveness and tolerability of immune-based treatments.

Werewolf’s research is based on its proprietary INDUKINE platform, which uses molecular masking and tumor-activated mechanisms to conditionally regulate immune-stimulating proteins.